AdAlta Ltd (ASX: 1AD) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
AdAlta Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
AdAlta Ltd (ASX: 1AD)
Latest News
Consumer Staples & Discretionary Shares
Up 19% in 2024, is it time to buy or sell Coles shares?
Share Market News
AdAlta (ASX:1AD) share price rockets 31% on United States FDA update
1AD ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About AdAlta Ltd
AdAlta Ltd is engaged in drug discovery and developing protein therapeutics, known as i-bodies, for treating a wide range of human diseases. The principal business of AdAlta is the discovery and development of next-generation protein and cell-based therapeutics. The i-body candidate, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases, for which current therapies are sub-optimal. Its pipeline includes Fibrosis and CAR-T cancer therapeutics.
1AD Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
01 Nov 2024 | $0.02 | $0.00 | 0.00% | 30,000 | $0.02 | $0.02 | $0.02 |
29 Oct 2024 | $0.02 | $0.00 | 0.00% | 90,057 | $0.02 | $0.02 | $0.02 |
28 Oct 2024 | $0.02 | $0.00 | 0.00% | 334,310 | $0.02 | $0.02 | $0.02 |
25 Oct 2024 | $0.02 | $0.00 | 0.00% | 429,850 | $0.02 | $0.02 | $0.02 |
24 Oct 2024 | $0.02 | $0.00 | 0.00% | 402,631 | $0.02 | $0.02 | $0.02 |
23 Oct 2024 | $0.02 | $0.00 | 0.00% | 1,087,182 | $0.02 | $0.02 | $0.02 |
22 Oct 2024 | $0.02 | $0.00 | 0.00% | 852,119 | $0.02 | $0.02 | $0.02 |
21 Oct 2024 | $0.02 | $0.00 | 0.00% | 25,966 | $0.02 | $0.02 | $0.02 |
18 Oct 2024 | $0.02 | $0.00 | 0.00% | 594,000 | $0.02 | $0.02 | $0.02 |
17 Oct 2024 | $0.02 | $0.00 | 0.00% | 52,952 | $0.02 | $0.02 | $0.02 |
16 Oct 2024 | $0.02 | $0.00 | 0.00% | 549,705 | $0.02 | $0.02 | $0.02 |
15 Oct 2024 | $0.02 | $0.00 | 0.00% | 90,000 | $0.02 | $0.02 | $0.02 |
14 Oct 2024 | $0.02 | $0.00 | 0.00% | 114,138 | $0.02 | $0.02 | $0.02 |
11 Oct 2024 | $0.02 | $0.00 | 0.00% | 1,058,586 | $0.02 | $0.02 | $0.02 |
10 Oct 2024 | $0.02 | $0.00 | 0.00% | 1,518,696 | $0.02 | $0.02 | $0.02 |
09 Oct 2024 | $0.02 | $0.00 | 0.00% | 352,681 | $0.02 | $0.02 | $0.02 |
08 Oct 2024 | $0.02 | $0.00 | 0.00% | 213,462 | $0.02 | $0.02 | $0.02 |
07 Oct 2024 | $0.02 | $0.00 | 0.00% | 4,087 | $0.02 | $0.02 | $0.02 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
06 Sep 2024 | Timothy Oldham | Buy | 100,000 | $2,195 |
On-market trade.
|
19 Dec 2023 | Robert Peach | Issued | 1,750,000 | $22,092 |
Issue of options. Black-Scholes valuation
|
19 Dec 2023 | David Fuller | Issued | 1,750,000 | $22,092 |
Issue of options. Black-Scholes valuation
|
19 Dec 2023 | Paul MacLeman | Issued | 2,800,000 | $35,347 |
Issue of options. Black-Scholes valuation, typo error
|
19 Dec 2023 | Timothy Oldham | Issued | 500,000 | $10,000 |
Issue of securities.
|
19 Dec 2023 | Timothy Oldham | Issued | 500,000 | $12,500 |
Issue of options.
|
19 Dec 2023 | Timothy Oldham | Issued | 5,600,000 | $70,694 |
Issue of options. Black-Scholes valuation
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Dr David Fuller | Non-Executive Director | Jul 2020 |
Dr Fuller has over 30 years of experience in pre-clinical, clinical development, medical and regulatory affairs with specialisations in early phase development and oncology.
|
Dr Paul MacLeman | Non-Executive ChairmanNon-Executive Director | Oct 2019 |
Dr MacLeman has expertise in capital management, business development, technology commercialisation and sales & marketing globally.
|
Dr Timothy Oldham | Managing DirectorChief Executive Officer | Oct 2019 |
Dr Oldham has more than 20 years of life sciences business development, alliance management, portfolio and product development, and commercialisation experience in Europe, Asia and Australia, with a particular focus on biologics, cell and gene therapies and pharmaceutical products.
|
Dr Robert Peach | Non-Executive Director | Nov 2016 |
Dr Peach has 30 years of drug discovery and development experience in the Pharmaceutical and Biotechnology industry.
|
Mr Cameron Jones | Chief Financial OfficerCompany Secretary | May 2017 |
-
|
Cameron Jones | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Sacavic Pty Ltd <Morris Super Fund A/C> | 97,441,722 | 16.36% |
HSBC Custody Nominees (Australia) Limited | 85,720,663 | 14.39% |
Fletcher Meurs Investments Pty Ltd | 27,029,924 | 4.54% |
YCLP Pty Ltd <Yclp A/C> | 27,029,924 | 4.54% |
Radiata Foundation Ltd | 20,560,519 | 3.45% |
Meurs Holdings Pty Ltd <P&M Meurs Superannuation A/C> | 20,123,655 | 3.38% |
Skiptan Pty Ltd <P&M Meurs Family A/C> | 19,407,256 | 3.26% |
Mr Tzu Hsuan Tseng | 9,893,171 | 1.66% |
BNP Paribas Nominees Pty Ltd <HUB24 Custodial Serv Ltd> | 7,058,296 | 1.19% |
Mr Craig Graeme Chapman <Nampac Discretionary A/C> | 5,000,000 | 0.84% |
Scintilla Strategic Investments Limited | 5,000,000 | 0.84% |
Mr John Okroglic | 4,693,397 | 0.79% |
Citycastle Pty Ltd | 4,302,320 | 0.72% |
Azzurra Investments Pty Ltd | 4,050,000 | 0.68% |
Mr Kevin John Cairns & Mrs Catherine Valerie Cairns <Cairns Family Super A/C> | 4,000,000 | 0.67% |
Mr Alistair David Strong | 4,000,000 | 0.67% |
Mr David John Robinson | 3,833,000 | 0.64% |
Mrs Gwen Murray Pfleger <Pfleger Family A/C> | 3,600,000 | 0.60% |
Mr Peera Maytha | 3,600,000 | 0.60% |
Castle Manor Pty Ltd <Arrendene Holdings A/C> | 3,503,904 | 0.59% |
Huon Pine Pty Ltd <Huon Pine Investment A/C> | 3,250,000 | 0.55% |
La Trobe University | 3,041,330 | 0.51% |
Mr Michael Peter Hetrelezis <Mike'S Investment A/C> | 3,000,000 | 0.50% |
Mr Kalpesh Varsani & Mrs Rita Varsani <Varsani Family S/F A/C> | 3,000,000 | 0.50% |
Andrew P O'Brien Holdings Pty Ltd <Andrew P O'Brien A/C> | 2,944,445 | 0.49% |